The demographic shift in China that is boosting the number of Chinese citizens over the age of 60 will have a profound impact on the country, but it also presents opportunities for investors as China struggles to enlarge its national health care system to keep up with the growth in this segment of the population.

LIGNET believes that several firms that trade on U.S. exchanges, including Chinese Mindray Medical Instruments (NYSE: MR) and American supplemental insurance firm Aflac (NYSE: AFL) are in a position to benefit from this rapidly growing market.

Click here to read the full analysis from top forecasters at LIGNET.com.